News
VSTM
--
0.00%
--
SCWorx, Oramed Pharmaceuticals leads healthcare gainers; AnPac Bio-Medical Science, Sientra among major losers
Gainers: SCWorx (WORX) +90%, Oramed Pharmaceuticals (ORMP) +31%, Rhythm Pharmaceuticals (RYTM) +19%, Genfit (GNFT) +15%, Verastem (VSTM) +13%.Losers: AnPac Bio-Medical Science (ANPC) -11%, Sientra (SIEN) -9%, Alphatec Holdings (ATEC) -5%, Metacrine (MTCR) -4%.
Seekingalpha · 1h ago
Mid-Morning Market Update: Markets Open Higher; Disney Laying Off 32,000 Workers
Following the market opening Friday, the Dow traded up 0.29% to 29,958.11 while the NASDAQ rose 0.86% to 12,198.84. The S&P also rose, gaining 0.35% to 3,642.29.
Benzinga · 1h ago
Does Verastem (NASDAQ:VSTM) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Simply Wall St. · 11/12 14:43
Verastem EPS beats by $0.04, beats on revenue
Verastem (VSTM): Q3 GAAP EPS of $0.08 beats by $0.04.Revenue of $78.65M (+773.9% Y/Y) beats by $52.18M (includes sale of COPIKTRA (duvelisib)).Cash, Cash Equivalents and Investments of $205.7M.Press Release
Seekingalpha · 11/09 21:43
Verastem Sees FY 2020 Operating Expenses Between $80M And $90M, Has Cash Runway Until At Least 2024
 Announced Positive Updated Data from Ongoing Investigator-Initiated Phase 1/2 FRAME Study Evaluating VS-6766 and Defactinib Combination in Patients with Low-Grade Serous Ovarian Cancer On Track to Commence
Benzinga · 11/09 21:26
Verastem Oncology Q3 EPS $0.11 Up From $(0.35) YoY, Sales $78.60M Up From $9.03M YoY
Verastem Oncology (NASDAQ:VSTM) reported quarterly earnings of $0.11 per share. This is a 131.43 percent increase over losses of $(0.35) per share from the same period last year. The company reported $78.60 million in
Benzinga · 11/09 21:25
TWTR, PINS, OSTK and TPR among premarket gainers
Universal Security Instruments (UUU) +87%.Cellect Biotechnology (APOP) +36%.Pinterest (PINS) +31% on Q3 results.Inphi Corporation (IPHI) +27% as the company will be acquired by Marvell in a cash and stock transaction.Xtant Medical Holdings (XTNT) +22% on Q3
Seekingalpha · 10/29 12:23
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase 39,000 shares of its common stock to three new employees and the grant of 22,500 restricted stock
Business Wire · 10/06 12:00
Verastem Oncology Announces Closing Of COPIKTRA Sale To Secura Bio
Verastem Now Focused on Development of VS-6766 and Defactinib Combination in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Registration-Directed Clinical Trials in LGSOC and KRAS Mutant
Benzinga · 09/30 12:57
Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has completed the sale of Verastem's COPIKTRA (duvelisib), a marketed oral inhibitor of phosphoinositide 3-kinase
Business Wire · 09/30 12:54
Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers
Gainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%.
Seekingalpha · 09/16 15:00
Verastem Oncology Signs Definitive Agreement To Sell COPIKTRA Rights To Secura Bio To Focus On Development Of VS-6766 And Defactinib In KRAS Mutant Solid Tumors; Co. Will Receive $70M Upfront Payment, Total Deal Value $311M
Verastem Will Receive $70 Million Up-Front with Total Deal Value Up to $311 Million, Plus Double-Digit Sales Royalties Upon Closing, Verastem's Current Programs Will Be Funded Until At Least 2024 to
Benzinga · 08/10 12:38
Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has entered into a definitive agreement to sell its global commercial and dev
Business Wire · 08/10 12:30
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 07/06 12:00
Verastem Oncology Highlights Presentation Of Preclinical Data Supporting Combo Of VS-6766, Defactinib In Metastatic Uveal Melanoma
Verastem, Inc. (NASDAQ:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from a study
Benzinga · 06/22 20:07
Billionaire Steven Cohen Bets Big on These 3 Stocks
TipRanks · 05/19 14:47
3 Biotech Stocks Under $4 With at Least 50% Upside Potential
TipRanks · 05/14 14:31
H.C. Wainwright Reiterates Buy on Verastem, Raises Price Target to $3
H.C. Wainwright analyst Sean Lee reiterates Verastem (NASDAQ:VSTM) with a Buy and raises the price target from $2.75 to $3.
Benzinga · 05/11 11:25
Verastem EPS misses by $0.14, beats on revenue
Verastem (NASDAQ:VSTM): Q1 GAAP EPS of -$0.35 misses by $0.14. Revenue of $5.06M (+203.0% Y/Y) beats by $1.18M. Cash, cash equivalents and short-term inves
seekingalpha · 05/08 02:10
Verastem Oncology Q4 EPS $(0.400) Beats $(0.450) Estimate, Sales $3.617M Miss $4.500M Estimate
Verastem Oncology (NASDAQ:VSTM) reported quarterly losses of $(0.400) per share which beat the analyst consensus estimate of $(0.450) by 11.11 percent. This is a 8.11 percent decrease over losses of $(0.370) per share
Benzinga · 05/07 20:51
Webull provides a variety of real-time VSTM stock news. You can receive the latest news about Verastem through multiple platforms. This information may help you make smarter investment decisions.
About VSTM
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.
More